These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 14583850

  • 1. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients.
    Fernández-Rivera J, García R, Lozano F, Macías J, García-García JA, Mira JA, Corzo JE, Gómez-Mateos J, Rueda A, Sánchez-Burson J, Pineda JA.
    HIV Clin Trials; 2003; 4(5):337-46. PubMed ID: 14583850
    [Abstract] [Full Text] [Related]

  • 2. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia.
    Brown TT, Ruppe MD, Kassner R, Kumar P, Kehoe T, Dobs AS, Timpone J.
    J Clin Endocrinol Metab; 2004 Mar; 89(3):1200-6. PubMed ID: 15001610
    [Abstract] [Full Text] [Related]

  • 3. [The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients].
    Guo FP, Yu XB, Luo L, Han Y, Qiu ZF, Zuo LY, Li YL, Yu W, Li TS.
    Zhonghua Nei Ke Za Zhi; 2010 Aug; 49(8):649-52. PubMed ID: 20979781
    [Abstract] [Full Text] [Related]

  • 4. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients.
    Madeddu G, Spanu A, Solinas P, Babudieri S, Calia GM, Lovigu C, Mannazzu M, Nuvoli S, Piras B, Bagella P, Mura MS, Madeddu G.
    Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4576-89. PubMed ID: 26698255
    [Abstract] [Full Text] [Related]

  • 5. Long-term use of protease inhibitors is associated with bone mineral density loss.
    Kinai E, Nishijima T, Mizushima D, Watanabe K, Aoki T, Honda H, Yazaki H, Genka I, Tanuma J, Teruya K, Tsukada K, Gatanaga H, Kikuchi Y, Oka S.
    AIDS Res Hum Retroviruses; 2014 Jun; 30(6):553-9. PubMed ID: 24494779
    [Abstract] [Full Text] [Related]

  • 6. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy.
    Madeddu G, Spanu A, Solinas P, Calia GM, Lovigu C, Chessa F, Mannazzu M, Falchi A, Mura MS, Madeddu G.
    Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):39-48. PubMed ID: 15195003
    [Abstract] [Full Text] [Related]

  • 7. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.
    Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, Katlama C, Costagliola D, ANRS 121 Hippocampe study group.
    AIDS; 2009 Apr 27; 23(7):817-24. PubMed ID: 19363330
    [Abstract] [Full Text] [Related]

  • 8. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy.
    Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Viganò A.
    AIDS; 2001 Sep 28; 15(14):1823-9. PubMed ID: 11579244
    [Abstract] [Full Text] [Related]

  • 9. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy.
    Carr A, Miller J, Eisman JA, Cooper DA.
    AIDS; 2001 Apr 13; 15(6):703-9. PubMed ID: 11371684
    [Abstract] [Full Text] [Related]

  • 10. [Influence of long-term highly active antiretroviral therapy on bone mineral density in HIV/AIDS patients].
    Su YB, Xie J, Han Y, Qiu ZF, Li YL, Song XJ, Yu W, Li TS.
    Zhonghua Yi Xue Za Zhi; 2012 May 08; 92(17):1155-8. PubMed ID: 22883000
    [Abstract] [Full Text] [Related]

  • 11. Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART).
    Bolland MJ, Grey A, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Gamble GD, Reid IR.
    Clin Endocrinol (Oxf); 2012 May 08; 76(5):643-8. PubMed ID: 22040002
    [Abstract] [Full Text] [Related]

  • 12. Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial.
    Hansen AB, Obel N, Nielsen H, Pedersen C, Gerstoft J.
    HIV Med; 2011 Mar 08; 12(3):157-65. PubMed ID: 20722752
    [Abstract] [Full Text] [Related]

  • 13. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors.
    Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N, Mercié P, Morlat P, Thiébaut R, Dabis F, Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.
    AIDS; 2008 Jan 30; 22(3):395-402. PubMed ID: 18195566
    [Abstract] [Full Text] [Related]

  • 14. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors.
    Goh SSL, Lai PSM, Tan ATB, Ponnampalavanar S.
    Osteoporos Int; 2018 Mar 30; 29(3):595-613. PubMed ID: 29159533
    [Abstract] [Full Text] [Related]

  • 15. Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia.
    Assoumou L, Katlama C, Viard JP, Bentata M, Simon A, Roux C, Kolta S, Costagliola D, Rozenberg S, ANRS Osteovir study group.
    AIDS; 2013 Sep 24; 27(15):2425-30. PubMed ID: 24029735
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of bone mineral density in Iranian HIV/AIDS patients.
    Badie BM, Soori T, Kheirandish P, Izadyar S, SeyedAlinagh S, Foroughi M, Rostamian A, Mohraz M.
    Acta Med Iran; 2011 Sep 24; 49(7):460-7. PubMed ID: 21960080
    [Abstract] [Full Text] [Related]

  • 17. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children.
    Mora S, Zamproni I, Beccio S, Bianchi R, Giacomet V, Viganò A.
    J Clin Endocrinol Metab; 2004 Jan 24; 89(1):24-8. PubMed ID: 14715822
    [Abstract] [Full Text] [Related]

  • 18. Prevalence and risk factors of osteopenia/osteoporosis in Turkish HIV/AIDS patients.
    Aydın OA, Karaosmanoglu HK, Karahasanoglu R, Tahmaz M, Nazlıcan O.
    Braz J Infect Dis; 2013 Jan 24; 17(6):707-11. PubMed ID: 24076108
    [Abstract] [Full Text] [Related]

  • 19. Prevalence and risk factors of low bone mineral density among perinatally HIV-infected Thai adolescents receiving antiretroviral therapy.
    Puthanakit T, Saksawad R, Bunupuradah T, Wittawatmongkol O, Chuanjaroen T, Ubolyam S, Chaiwatanarat T, Nakavachara P, Maleesatharn A, Chokephaibulkit K.
    J Acquir Immune Defic Syndr; 2012 Dec 01; 61(4):477-83. PubMed ID: 22918157
    [Abstract] [Full Text] [Related]

  • 20. Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir.
    Rivas P, Górgolas M, García-Delgado R, Díaz-Curiel M, Goyenechea A, Fernández-Guerrero ML.
    HIV Med; 2008 Feb 01; 9(2):89-95. PubMed ID: 18093130
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.